QurAlis Archives – Droia Ventures

11 Dec QurAlis’ selective Kv7 opener, a drug candidate for ALS, demonstrates up to 20-fold increase in potency and dramatic reduction in side effects compared to Retigabine in preclinical models

Posted at 18:18h in Press releases, QurAlis

QurAlis' announces the results of extensive pre-clinical studies on its lead program for ALS patients: QRA-244 shows comparable effects to retigabine and dramatic reductions in side effects....

29 Oct QurAlis Announces Appointment of new Chief Medical Officer and Formation of Clinical Advisory Board

Posted at 09:43h in Press releases, QurAlis

The company also announced the formation of its Clinical Advisory Board, which will work closely with Dr. Genge on QurAlis’ clinical research and development programs in ALS and frontotemporal dementia (FTD) as the company prepares to move its pipeline to the clinical stage....

01 Jul QurAlis Announces Agreement to Strengthen ALS Pipeline

Posted at 09:52h in Press releases, QurAlis

QurAlis' announces the results of extensive pre-clinical studies on its lead program for ALS patients: QRA-244 shows comparable effects to retigabine and dramatic reductions in side effects....

13 May QurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS)

Posted at 10:02h in Press releases, QurAlis

The financing was led by LS Polaris Innovation Fund, lead seed investor Mission BioCapital, INKEF Capital and the Dementia Discovery Fund, and co-led by Droia Ventures. Additional new investors include Mitsui Global Investment and Dolby Family Ventures, joined by investments from existing investors Amgen Ventures,...